argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
A retrospective study found that myocarditis within the first month after immune checkpoint inhibitor initiation was linked to higher mortality risk. The analysis identified 4,635 cases in VigiBase.
A 24-year-old woman with refractory lupus achieved two successful pregnancies following dual-target CAR-T cell therapy, while bispecific T cell engagers showed efficacy in treatment-refractory antisynthetase syndrome and systemic sclerosis patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778446 |
A Study to Test CRT-402 in Refractory Autoimmune Disease |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07775235 |
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease |
RECRUITING | |
| NCT07668505 |
Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies |
NOT_YET_RECRUITING | PHASE4 |
| NCT06991114 |
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. |
RECRUITING | PHASE2 |
| NCT06925542 |
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease |
RECRUITING | PHASE1 |
| NCT05979441 |
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT05895786 |
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] |
RECRUITING | PHASE3 |
| NCT05523167 |
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. |
COMPLETED | PHASE2/PHASE3 |
| NCT05379634 |
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01734369 |
Environmental Risk Factors for Myositis in Military Personnel |
COMPLETED |
